A randomized, 24 weeks, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of omalizumab in adult patients with chronic urticaria who exhibit IgE against thyreoperoxidase.

Trial Profile

A randomized, 24 weeks, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of omalizumab in adult patients with chronic urticaria who exhibit IgE against thyreoperoxidase.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2014

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Urticaria
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 20 May 2009 Actual patient number (51) added as reported by ClinicalTrials.gov.
    • 20 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top